Mark your calendars! ASPIRE-IOTOX Symposium April 24-25, 2026 at MD Anderson Cancer Center #irAE #immunotherapy @sitcancer.bsky.social @ascocancer.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social @mdanderson.bsky.social

Starting soon! More great #irAE content at #ASCO25, including CAR-T and BiTES @kmittalmd.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social #ASPIRE

@mazietsangmd.bsky.social describing how to "connect the dots" of #irAE multidisciplinary management across academic and community cancer centers #ASPIRE @ascocancer.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social

Did you know the ICD10 codes to identify patients experiencing immunotherapy toxicity? @kmittalmd.bsky.social presents these codes as a system-based approach to capture #irAE impact @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @mazietsangmd.bsky.social @ascocancer.bsky.social

@kmittalmd.bsky.social presents #ASPIRE #ASCO25 community united in "Advancing Clinical Care, Research, and Advocacy in Immunotherapy-Related Adverse Events" #irAE @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @ascocancer.bsky.social @mazietsangmd.bsky.social @advocatecollab.bsky.social

Kathryn Bollin, MD's #ASCO25 community oncology perspective on "Getting Practical About Care Transitions" in patients with #irAE #OncSky. "Access to immunotherapy has far outpaced evidence to inform how to manage the related side effects" @ascocancer.bsky.social #ASPIRE @pateloncology.bsky.social

@kerryreynoldsmd.bsky.social presents the "The Who, What, Where of immunotherapy toxicity" #ASCO25 #ASPIRE @kmittalmd.bsky.social @funchainmd.bsky.social @mazietsangmd.bsky.social

🎉 Big news! Today marks the first gathering of ASCO's latest COP—ASPIRE! 🚀 Join us for the #ASPIRE COP meeting TODAY from 4-6 PM CST in Room E253cd. Let’s connect and collaborate! Don’t miss out! 🤝✨ @ascocancer.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social

🚨 #irAE aficionados! 2nd #ASPirE Case Discussion series TODAY - apparently y'all like talking about irAE cases!
🗓️ Tues May 20
⏰ 6:30pm EDT/3:30pm PDT
Feat. endocrine & cardiac cases
Hosted by Dr. Mimi Wang @ascocancer.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social

🚨 New from @ascocancer.bsky.social ! #ASPIRE is the #ASCO25 community of practice for all #irAE. Oncologists, nurses, pharmacists AND non-oncology subspecialists —join now for FREE (limited time)! 💥
🔗 t.co/Pv8p49MJ2L
@amergastroassn.bsky.social @jrheumatol.bsky.social @societyhospmed.bsky.social

Heading to #ASCO25 this year? Be sure to join us for the first ever #ASPIRE Community of Practice on Friday, May 30th: 4-6pm CST in E253cd. We have a great agenda and opportunity to connect with other #irAE aficionados @ascocancer.bsky.social @funchainmd.bsky.social www.asco.org/annual-meeti...

“What does #ASPIRE mean to you ?”
Hear from our members about why YOU should join the ASCO ASPIRE COP #irAE #ASCO25
@ascocancer.bsky.social @kerryreynoldsmd.bsky.social @funchainmd.bsky.social @ericroeland.bsky.social
@kmittalmd.bsky.social @oncodaily.bsky.social @sitcancer.bsky.social

Interested in #irAEs? Join the Alliance for Support and Prevention of Immune-Related Adverse Events #ASPIRE
Follow QR code or Google Form docs.google.com/forms/d/1zfl...
@funchainmd.bsky.social
@kerryreynoldsmd.bsky.social
@kmittalmd.bsky.social @ascocancer.bsky.social
@oncodaily.bsky.social